12:00 AM
 | 
Oct 28, 2002
 |  BioCentury  |  Finance

BT earnings vs. RX earnings

BT earnings vs. RX earnings

Biotech Group 3Q EPS est 3Q EPS actual Outcome 10/25 cls Wk chg % chg Mkt cap chg 10/25mkt cap Notes
Affymetrix (AFFX) $0.03 $0.05 Beat by $0.02 $24.79 $0.80 3% $46 $1,440 Continued growth of GeneChip systems
Amgen (AMGN) $0.32 $0.34 Beat by $0.02 $49.79 -$0.69 -1% -$857 $61,824 Strong growth across key product lines, with the exception of Enbrel for rheumatoid arthritis, which continues to have manufacturing constraints
Applied Bio (ABI)(A) $0.15 $0.16 Beat...

Read the full 653 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >